MedTrace Logo

Long Term Safety and Efficacy of SC Apomorphine in Treatment of "Off" Episodes in Late-Stage Parkinson's Disease

NCT00142545 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 800

Last updated 2005-09-02

No results posted yet for this study

Summary

The current protocol is designed to satisfy the need for a compassionate use treatment protocol as well as for a long-term open label follow-up study.

Conditions

  • Parkinson Disease

Interventions

DRUG

apomorphine HCl injection

Sponsors & Collaborators

  • Mylan Bertek Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Will Sullivan · Mylan Bertek Pharmaceuticals

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-07-31
Completion
2005-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00142545 on ClinicalTrials.gov